A Randomized, Double-Blind, Placebo-Controlled Study of a Multispecies Probiotic Mixture in Non-Alcoholic Fat ty Liver Disease = A Randomized, Double-Blind, Placebo-Controlled Study of a Multispecies Probiotic Mixture in Non-Alcoholic Fat ty Liver Disease

다국어 초록 (Multilingual Abstract)

Aims: Intestinal microbiota is known to be closely associated with the incidence of obesity and nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate effects of probiotics treatment on visceral fat area (VFA) and intrahepatic fat (IHF) fraction in NAFLD.
Methods: Sixty-eight obese NAFLD patients (>5% fat fraction using MRI-derived proton density fat fraction (PDFF)) divided into the probiotics and the placebo group for twelve weeks. The probiotics mixture consists of six kinds of probiotics. VFA and IHF measured by MRI-PDFF. Body fat and muscle composition was evaluated by multi-frequency bioimpedence analysis. Liver stiffness was measured by transient elastography.
Results: Body weight and total body fat amount were more reduced in probiotics group compare to placebo group. IHF fraction (16.3±15.0à14.1±7.7, P=0.032) reduced after 12 weeks probiotics treatment compare to baseline, but not in placebo group. Reduction rate of IHF (mean difference: -2.61%, P=0.012) was also more in probiotics group compare to placebo. Triglyceride level reduced after 12 weeks probiotics treatment compare to baseline. Probiotics group showed also more decrease triglyceride concentration (mean difference; -34.0 mg/dl, P=0.0033). Deep sequencing of the fecal microbiome revealed that the amount of Agathobaculum, Dorea (OTU 527923), Blautia, Ruminoccous, and Dorea (OTU 195044, OUT 470168) were increased in patients who were improved fatty liver.
Conclusions: The 12-week treatment of probiotics resulted in a significant reduction of IHF and BMI in obese NAFLD patients.